Treatment of Hepatocellular Carcinoma
and Current Situation in the Czech Republic
Oliverius M., Bělina F.*, Novotný J.**, Studeník P.***, Pudil J.*, Ryska M.*
Klinika transplantační chirurgie IKEM, Praha, přednosta: prof. MUDr. M. Adamec, CSc. *Chirurgická klinika 2. LF UK a ÚVN, Praha, přednosta: prof. MUDr. M. Ryska, CSc. **Komplexní onkologické centrum, Praha, přednosta: doc. L. Petruželka, CSc. ***Centrum kardiovaskulární a transplantační chirurgie, Brno, ředitel: prof. MUDr. J. Černý, DrSc |
|
Summary:
Hepatocelullar carcinoma (HCC) is the commonest primary liver malignacy. Its incidence is increasing worldwide. In the Czech
Republic, about 250 new cases are reported per year. The patient’s prognosis depends on early diagnosis and initiation of a correct therapeutical
procedure. During the decision making process, tumor staging, as well as the chronic liver disease stage, must be considered. Surgery,
i.e. liver resection or transplantation, is the only potentially curable method. Other treatment options include chemoembolization,
radiofrequency ablation, alcoholization and, currently poorly effective systemic chemotherapy.
Current monitoring of the radical procedures in the Czech Republic is unsatisfactory. Although surgical treatment has been performed
by many clinics, based on the available data, none of the following could be assessed: the number of surgically managed HCC patients
in the Czech Republic per year, disease staging in these patients and their short-term and long-term treatment outcomes.
In the Czech Republic, 45 liver transplantations have been performed, data on resection procedures are not available.
The aim of the authors is to support the Central HCC Patient Registry, presented at the following website: www.koc.cz.
Key words:
hepatocellular carcinoma – liver resection – liver transplantation – Milano criteria – National Patient Registry
|